Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
about
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.Use of polyclonal/monoclonal antibody therapies in transplantation.Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.Donor-Specific Antibodies in Kidney Transplant Recipients.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy.A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.Transplant glomerulopathy.Antibody-mediated rejection: New approaches in prevention and management.Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.Thrombotic microangiopathy after renal transplantation: Current insights in and recurrent diseaseTreatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results
P2860
Q38668319-0E2B2922-96EA-45C4-99FF-518E53E0A52BQ38769922-558DADEE-AA39-4621-9115-AB42D5E556B5Q38930294-7931A9DC-97C0-41F2-AF37-5715D30E67FCQ39265221-CF843F70-C8FD-4FE3-98DC-31535D653009Q42086661-24DD4B16-61EA-4689-98A0-E078C4B80A01Q42174325-DE9899FE-8DE7-4288-96C6-8D0E129CED9BQ42359412-506AF512-7012-4B98-BB90-7C2D1CB96555Q46970385-6DEFA3D0-5278-47F0-B14E-AB980ECAB0A3Q47238226-84E8D05E-A2FD-4122-9F1F-17352D67B6D9Q47292306-D4AE2239-5B5A-4362-934B-A252E23C2C82Q47694251-3D82B4D4-34DF-41D1-AA87-47CD7574111CQ47920746-14B31B2E-A4FA-499F-9292-85961B02CF9BQ50063069-56CD5AA5-C0BB-4532-9C20-EFE56D352A62Q52401610-792441BE-9D95-47EA-8D5F-2BA8F69CF445Q54969814-374DC830-046A-47B3-AFF0-9F1785DAC452Q58754943-92BA951A-2FB5-4094-BDF7-155FF90B5291Q58754949-C0585E90-59A9-4961-9AF2-A3A4AA58A227
P2860
Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Eculizumab Therapy for Chronic ...... t Randomized Controlled Trial.
@en
Eculizumab Therapy for Chronic ...... t Randomized Controlled Trial.
@nl
type
label
Eculizumab Therapy for Chronic ...... t Randomized Controlled Trial.
@en
Eculizumab Therapy for Chronic ...... t Randomized Controlled Trial.
@nl
prefLabel
Eculizumab Therapy for Chronic ...... t Randomized Controlled Trial.
@en
Eculizumab Therapy for Chronic ...... t Randomized Controlled Trial.
@nl
P2093
P2860
P356
P1476
Eculizumab Therapy for Chronic ...... ot Randomized Controlled Trial
@en
P2093
N C Kirkiles-Smith
R N Formica
S Kulkarni
V Broecker
P2860
P304
P356
10.1111/AJT.14001
P407
P577
2016-09-16T00:00:00Z